Stk11 Serine Threonine Kinase 11 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[^1]
[^2]
[^3]
[^4]
[^5]
[^6]
[^7]
[^8]
[^9]
[^10]
| Full Name | Serine/Threonine Kinase 11 (LKB1) |
|---|
| Chromosome | 19p13.3 |
|---|
| NCBI Gene ID | 6794 |
|---|
| OMIM | 602216 |
|---|
| Ensembl ID | ENSG00000118046 |
|---|
| UniProt ID | Q15831 |
|---|
| Protein Length | 433 amino acids |
|---|
| Protein Family | STK11 family, AMPK-related kinases |
|---|
| Associated Diseases | Peutz-Jeghers Syndrome, Alzheimer's Disease, Parkinson's Disease, Cancer |
|---|
STK11 (Serine/Threonine Kinase 11), more commonly known as LKB1 (Liver Kinase B1), is a master upstream kinase that plays a central role in cellular energy metabolism, stress responses, and cell polarity. LKB1 activates the AMPK (AMP-activated protein kinase) family of kinases, which serve as primary energy sensors that regulate metabolic homeostasis, autophagy, mitochondrial biogenesis, and cell growth.
In neurons, LKB1 is essential for establishing neuronal polarity, axon specification, and synaptic function. Loss of LKB1 function contributes to neurodegeneration through impaired energy homeostasis, reduced autophagy, and altered mitochondrial dynamics. Germline mutations in STK11 cause Peutz-Jeghers Syndrome, a hereditary cancer predisposition syndrome, while somatic mutations are common in various cancers.
¶ Gene Structure and Expression
The STK11 gene is located on chromosome 19p13.3 and encodes a serine/threonine protein kinase of 433 amino acids. The gene contains 9 exons and undergoes alternative splicing to produce multiple isoforms. LKB1 is ubiquitously expressed with high levels in epithelial cells, neurons, and metabolic tissues including liver, muscle, and adipose tissue.
¶ Protein Structure and Function
LKB1 is a member of the CaMK (Calcium/Calmodulin-dependent Kinase) family but lacks calcium-binding domains:
¶ Kinase Domain
- Catalytic domain in the N-terminus (residues 1-270)
- Binds ATP and phosphorylates target proteins
- Activity requires association with two accessory subunits: STRAD and MO25
- C-terminal domain mediates protein-protein interactions
- Dimerization is required for activity
- Phosphorylation at multiple sites regulates stability and function
- Phosphorylates 14 AMPK family kinases (AMPKα1/α2, BRSK1/2, MARK1-4, NUAK1/2, SIK1-3, SNRK)
- Activates downstream pathways for energy homeostasis
- Activates AMPK when ATP levels fall (high AMP/ATP ratio)
- Triggers metabolic adaptation to restore energy balance
- Inhibits anabolic pathways (fatty acid synthesis, cholesterol synthesis)
- Activates catabolic pathways (fatty acid oxidation, autophagy)
- Increases glucose uptake via GLUT4 translocation
- Enhances fatty acid oxidation in mitochondria
- Promotes mitochondrial biogenesis via PGC-1α
- Regulates lipid metabolism
- Phosphorylates and activates ULK1
- Initiates autophagy cascade
- Essential for mitophagy and clearance of damaged organelles
- Prevents accumulation of protein aggregates
- Essential for neuronal polarity and axon specification
- Regulates microtubule dynamics
- Controls dendritic arborization
- Modulates synaptic plasticity
LKB1/AMPK dysfunction contributes to AD pathogenesis:
- Energy metabolism: Impaired glucose metabolism in AD brain
- Autophagy defects: Reduced autophagic clearance of Aβ and tau
- Mitochondrial dysfunction: Impaired mitochondrial biogenesis
- Synaptic failure: Altered synaptic plasticity mechanisms
- mTOR dysregulation: Cross-talk between LKB1-AMPK and mTOR pathways
LKB1 implications in PD include:
- Mitophagy impairment: Reduced clearance of damaged mitochondria
- α-synuclein toxicity: Altered protein quality control
- Dopaminergic neuron vulnerability: Energy deficiency in SNc neurons
- LRRK2 interactions: LRRK2 can phosphorylate AMPK
- Autosomal dominant disorder caused by STK11 mutations
- Characterized by mucocutaneous pigmentation
- Gastrointestinal hamartomatous polyps
- Increased cancer risk (breast, colorectal, pancreatic, stomach)
Targeting LKB1-AMPK pathway offers therapeutic opportunities:
- Metformin: Indirect LKB1-AMPK activator (most widely used)
- AICAR: Direct AMPK agonist
- Natural compounds: Berberine, resveratrol
- Small molecule LKB1 activators
- Gene therapy approaches
- LKB1 activation with autophagy enhancers
- Mitochondrial protectants combined with AMPK activators
- Metabolic modulators for neurodegeneration
The study of Stk11 Serine Threonine Kinase 11 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.